Ca&Bone

[XIIITH OROM CONGRESS]

APRIL 15, 2009

Ca&Bone - 2009;12(01)

[xiiith orom congress 2009;12(01)]

COMMENTS

0 comments

Further articles in this publication

Ca&Bone

[Antiresorption - same goal, different ways]

HORVÁTH CSABA

[Antiresorption - same goal, different ways]

Ca&Bone

[MOOT NEWS]

HORVÁTH CSABA

[2009;12(01) Moot News]

Ca&Bone

[Dear Readers and Colleagues!]

HORVÁTH CSABA

Ca&Bone

[RANKL-specific denosumab in the treatment of osteoporosis - Possible adverse effects of long-term use]

TANKÓ László

[According to the results of a recent clinical trial, the antiresorptive effect of a single 60-mg injection of denosumab, a monoclonal antibody specific to RANKL (receptor activator of NFκB ligand) substantially exceeds the effect of alendronate (70 mg weekly). Despite these differences, 1-year increases in bone density at the lumbar spine are virtually identical for both agents. The author summarizes experimental and clinical observations illustrating potential consequences of osteoclast deficiency and a constantly low rate of bone resorption for osteoblast function, bone mineralization, bone quality parameters, and mechanical properties, which all may have important implications for bone fragility. These observations also raise the question whether treatment efficiency is truly improved by aggressively pushing the limits of antiresorptive action.]

Ca&Bone

[Denosumab - pharmacokinetic and clinical evidences]

MÉSZÁROS SZILVIA

[Denosumab is a fully human monoclonal antibody to RANKL modifying bone resorption in a rapid, sustained and reversible way. In postmenopausal women with low bone mineral density, denosumab 60 mg every 6 months increased mineral density, and reduced bone turnover. In postmenopausal women, it reduced the risk of vertebral, hip, and non-vertebral fractures. Increase in body mass index and reduction in bone turnover was more pronounced with denosumab than with alendronate. In patients who were switched from alendronate to denosumab, positive effects on bone were more pronounced than in those continuing alendronate. Denosumab was safe and well tolerated, and it holds the promise of becoming an efficacious therapy for postmenopausal osteoporosis.]

All articles in the issue

Related contents

Ca&Bone

[Osteology Congress]

[Osteology Congress, 2007;10(01)]

Ca&Bone

[7th Congress of OROM]

SOMOGYI Péter

[Lakatos Péter the president of MOOT, started the congress after the opening ceremony, with a speech about the osteoporosis medicine therapy.]

Clinical Neuroscience

[Congress calendar]

[Congress calendar 2011;64(07-08)]

Clinical Neuroscience

[CONGRESS CALENDAR]

[Congress calendar 2007;60(01-02)]

Ca&Bone

[Forthcoming congress]

[ 2004;7(02)]